Introduction
Quinolones are a particularly attractive therapeutic option for pneumococcal respiratory tract infections in regions where there has been an increase in strains with high-level penicillin resistance associated with macrolide resistance. 1 In a 1996-1997 Spanish nationwide surveillance study, 60% of Streptococcus pneumoniae were resistant to penicillin (36.5% high-level resistance, 23.6% intermediate strains). 1 Fifty-three per cent of high-level penicillin-resistant strains were also macrolide resistant. 1 In the adult population, in which quinolones are mainly used, 22.6% of strains had a ciprofloxacin MIC у 2 mg/L, 6% an MIC у 4 mg/L, 1.9% an MIC у 8 mg/L and 0.6% an MIC у 16 mg/L. 2 Isolates with higher ciprofloxacin MICs have variable susceptibility to new fluoroquinolones, as suggested in a previous study where MICs of trovafloxacin were higher than those of gemifloxacin. 3 While several studies have concluded that the in vitro susceptibility to new quinolones is not influenced by the presence of serum in the media, 4,5 this has not been extensively studied for all new fluoroquinolones such as gemifloxacin.
This study explores the activity of five new quinolones against isolates with reduced susceptibility to ciprofloxacin, and the effect of the presence of human serum on the resistance rate.
Materials and methods
In a Spanish nationwide surveillance programme (1998) (1999) , 60 S. pneumoniae strains, recently isolated from adult patients with community-acquired respiratory tract infections, were tested against ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, clinafloxacin and gemifloxacin. Strains were chosen that had an MIC of ciprofloxacin у0.5 mg/L (14 strains with MIC 0.5 mg/L, 10 with MIC 1 mg/L, eight with MIC 2 mg/L, 11 with MIC 4 mg/L and 17 with MIC у 8 mg/L).
Susceptibility was determined using a broth microdilution method. MICs and MBCs were measured using Todd-Hewitt broth as the culture medium. To evaluate the effect of the presence of human serum, MICs and MBCs were also determined using 80% human serum (from a serum pool obtained from healthy donors who had not undergone drug treatment in the previous month) and 20% Todd-Hewitt broth. The final inoculum was 5 ϫ 10 5 cfu/mL. Cultures were incubated for 24 h at 35ЊC in 5% CO 2 . Strains were tested in triplicate, and modal MIC and MIC 90 values were calculated. S. pneumoniae ATCC 49619 was used as the control strain. Percentages of resistance were calculated using the susceptibility breakpoints for levofloxacin (р2 mg/L), trovafloxacin (р1 mg/L) and moxifloxacin (р1 mg/L) established by the NCCLS, 6 a suscept- ibility breakpoint of р2 mg/L for ciprofloxacin (there being no NCCLS breakpoint) 2 and a susceptibility breakpoint of р1 mg/L (similar to the value for new quinolones) for clinafloxacin and gemifloxacin.
Results and discussion
MIC 90 s and percentages of resistance (with and without human serum) of all six quinolones for strains of S. pneumoniae with increasing ciprofloxacin MICs in broth are shown in the Table. For all five new quinolones, 100% susceptibility was obtained for all strains with a ciprofloxacin MIC р 2 mg/L when tested with and without serum. The highest intrinsic activity was obtained for moxifloxacin, clinafloxacin and gemifloxacin with MIC 90 s in broth of р0.06 mg/L; the lowest intrinsic activity of new quinolones was obtained for levofloxacin with an MIC 90 in broth of 1 mg/L.
The problem arose with a ciprofloxacin MIC of у4 mg/L, where resistance rates of 9, 18 and 9% were obtained for levofloxacin, trovafloxacin and moxifloxacin, respectively. The resistance rates increased to у65% for these three quinolones when isolates with a ciprofloxacin MIC of 16 mg/L were tested. All these highly ciprofloxacin-resistant strains were susceptible to clinafloxacin and gemifloxacin. This may be important in the clinical setting, 7 where there are increasing rates of ciprofloxacin resistance. 2 Although other studies have concluded that the presence of human serum does not influence the intrinsic activity of some new quinolones, 4,5 the results of this study suggest that this conclusion cannot be extended to all fluoroquinolones. Other authors have shown that serum has no influence on the resistance rates for moxifloxacin. 5 For the other quinolones the influence of serum is significant for isolates with a ciprofloxacin MIC of у4 mg/L, since when the strains are tested in the presence of serum, the MIC measured exceeded the breakpoint. Differences from studies published previously 4, 5, 8 could be the result of the fact that the percentage of serum used in this study (80%) is higher than that used before (up to 50% serum), 4, 8 and may be due to the MIC distribution of the strains tested. The effect of serum could not be attributed exclusively to protein binding since it is lower for ciprofloxacin (30%) 9 than for moxifloxacin (50%), 9 where the effect is not observed.
In conclusion, considering both factors (using strains with higher ciprofloxacin MICs and the presence of human serum), gemifloxacin and clinafloxacin exhibited the lowest MIC 90 values (0.5 and 1 mg/L without and with serum, respectively) for the whole population of S. pneumoniae with ciprofloxacin MICs of у0.5 mg/L, and the lowest resistance rates (0 and р10% without and with serum, respectively). The other new quinolones (levofloxacin, trovafloxacin and moxifloxacin) exhibited resistance rates of у22% for the population tested, with less activity against strains with higher ciprofloxacin MICs. 
